Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Pituitary
Published in: Pituitary 4/2023

07-06-2023 | Research

[68 Ga]-DOTATATE PET/MR-based evaluation of physiologic somatostatin receptor 2 expression in the adult pituitary gland as a function of age and sex in a prospective cohort

Authors: Sean H. Kim, Se Jung Chris Chang, Georgiana Dobri, Sara Strauss, Eaton Lin, Vaz Zavaletta, Susan C. Pannullo, Joseph R. Osborne, Theodore H. Schwartz, Jonathan P. S. Knisely, Jana Ivanidze

Published in: Pituitary | Issue 4/2023

Login to get access

Abstract

Purpose

The pituitary gland has the fourth highest physiologic avidity of [68 Ga]-DOTATATE. In order to guide our understanding of [68 Ga]-DOTATATE PET in clinical contexts, accurate characterization of the normal pituitary gland is first required. This study aimed to characterize the normal pituitary gland using dedicated brain [68 Ga]-DOTATATE PET/MRI as a function of age and sex.

Methods

A total of 95 patients with a normal pituitary gland underwent brain [68 Ga]-DOTATATE PET examinations for the purpose of diagnosing CNS SSTR2 positive tumors (mean age: 58.9, 73% female). Maximum SUV of the pituitary gland was obtained in each patient. SUV of superior sagittal sinus was obtained to calculate normalized SUV score (SUVR) of the gland. The anatomic size of the gland was collected as maximum sagittal height (MSH). Correlations with age and sex were analyzed.

Results

The mean SUV and SUVR of the pituitary gland were 17.6 (range: 7–59.5, SD = 7.1) and 13.8 (range: 3.3–52.6, SD = 7.2), respectively. Older females had significantly higher SUV of the pituitary gland compared to younger females. When stratified by age and sex, both older and younger females had significantly higher pituitary SUV than older males. SUVR did not differ significantly by age or sex. MSH of the pituitary gland in younger females was significantly greater than in younger males at all age cutoffs.

Conclusion

This study provides an empiric profiling of the physiological [68 Ga]-DOTATATE avidity of the pituitary gland. The findings suggest that SUV may vary by age and sex and can help guide the use of [68 Ga]-DOTATATE PET/MRI in clinical and research settings. Future studies can build on these findings to investigate further the relationship between pituitary biology and demographic factors.
Literature
1.
Eigler T, Ben-Shlomo A (2014) Somatostatin system: molecular mechanisms regulating anterior pituitary hormones. J Mol Endocrinol 53:R1-19PubMedCrossRef
2.
Panetta R, Patel YC (1995) Expression of mRNA for all five human somatostatin receptors (hSSTR1-5) in pituitary tumors. Life Sci 56:333–342PubMedCrossRef
3.
Tebani A, Jotanovic J, Hekmati N et al (2021) Annotation of pituitary neuroendocrine tumors with genome-wide expression analysis. Acta Neuropathol Commun 9:181PubMedPubMedCentralCrossRef
4.
5.
Thodou E, Kontogeorgos G (2020) Somatostatin receptor profile in pituitary thyrotroph adenomas. Clin Neurol Neurosurg 195:105865PubMedCrossRef
6.
Vieria Neto L, Wildemberg LE, Colli LM et al (2013) ZAC1 and SSTR2 are downregulated in non-functioning pituitary adenomas but not in somatotropinomas. PLoS ONE 8:e77406PubMedPubMedCentralCrossRef
7.
Nishioka H, Tamura K, Iida H et al (2011) Co-expression of somatostatin receptor subtypes and estrogen receptor-α mRNAs by non-functioning pituitary adenomas in young patients. Mol Cell Endocrinol 331:73–78PubMedCrossRef
8.
Taboada GF, Luque RM, Bastos W et al (2007) Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas. Eur J Endocrinol 156:65–74PubMedCrossRef
9.
Øystese KA, Casar-Borota O, Normann KR, Zucknick M, Berg JP, Bollerslev J (2017) Estrogen receptor α, a sex-dependent predictor of aggressiveness in nonfunctioning pituitary adenomas: SSTR and sex hormone receptor distribution in NFPA. J Clin Endocrinol Metab 102:3581–3590PubMedCrossRef
10.
Tjörnstrand A, Casar-Borota O, Heurling K et al (2020) Lower (68) Ga-DOTATOC uptake in nonfunctioning pituitary neuroendocrine tumours compared to normal pituitary gland-A proof-of-concept study. Clin Endocrinol (Oxf) 92:222–231PubMedCrossRef
11.
Fusco A, Giampietro A, Bianchi A et al (2012) Treatment with octreotide LAR in clinically non-functioning pituitary adenoma: results from a case-control study. Pituitary 15:571–578PubMedCrossRef
12.
Ramírez C, Cheng S, Vargas G et al (2012) Expression of Ki-67, PTTG1, FGFR4, and SSTR 2, 3, and 5 in nonfunctioning pituitary adenomas: a high throughput TMA, immunohistochemical study. J Clin Endocrinol Metab 97:1745–1751PubMedCrossRef
13.
Gabalec F, Drastikova M, Cesak T et al (2015) Dopamine 2 and somatostatin 1–5 receptors coexpression in clinically non-functioning pituitary adenomas. Physiol Res 64:369–377PubMedCrossRef
14.
Reubi JC, Schar JC, Waser B et al (2000) Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 27:273–282PubMedCrossRef
15.
Ozguven S, Filizoglu N, Kesim S et al (2021) Physiological Biodistribution of (68)Ga-DOTA-TATE in Normal Subjects. Mol Imaging Radionucl Ther 30:39–46PubMedPubMedCentralCrossRef
16.
17.
Kunz WG, Jungblut LM, Kazmierczak PM et al (2017) Improved detection of transosseous meningiomas using (68)Ga-DOTATATE PET/CT compared with contrast-enhanced MRI. J Nucl Med 58:1580–1587PubMedCrossRef
18.
Ivanidze J, Roytman M, Lin E et al (2019) Gallium-68 DOTATATE PET in the evaluation of Intracranial Meningiomas. J Neuroimaging 29:650–656PubMedCrossRef
19.
20.
Kim SH, Roytman M, Kamen E et al (2021) [68Ga]-DOTATATE PET/MRI in the diagnosis and management of recurrent head and neck paraganglioma with spinal metastasis. Clin Imaging 79:314–318PubMedCrossRef
21.
Kim SH, Roytman M, Madera G et al (2022) Evaluating diagnostic accuracy and determining optimal diagnostic thresholds of different approaches to [(68)Ga]-DOTATATE PET/MRI analysis in patients with meningioma. Sci Rep 12:9256PubMedPubMedCentralCrossRef
22.
Sen R, Sen C, Pack J et al (2017) Role of high-resolution dynamic contrast-enhanced mri with golden-angle radial sparse parallel reconstruction to identify the normal pituitary gland in patients with macroadenomas. AJNR Am J Neuroradiol 38:1117–1121PubMedPubMedCentralCrossRef
23.
Berntsen EM, Haukedal MD, Håberg AK (2021) Normative data for pituitary size and volume in the general population between 50 and 66 years. Pituitary 24:737–745PubMedPubMedCentralCrossRef
24.
Sari S, Sari E, Akgun V et al (2014) Measures of pituitary gland and stalk: from neonate to adolescence. J Pediatr Endocrinol Metab 27:1071–1076PubMed
25.
Singh AKC, Kandasamy D, Garg A, Jyotsna VP, Khadgawat R (2018) Study of pituitary morphometry using MRI in Indian subjects. Indian J Endocrinol Metab 22:605–609PubMedPubMedCentralCrossRef
26.
Wang H, Hou B, Lu L et al (2018) PET/MRI in the diagnosis of hormone-producing pituitary microadenoma: a prospective pilot study. J Nucl Med 59:523–528PubMedCrossRef
27.
Zhao X, Xiao J, Xing B, Wang R, Zhu Z, Li F (2014) Comparison of (68)Ga DOTATATE to 18F-FDG uptake is useful in the differentiation of residual or recurrent pituitary adenoma from the remaining pituitary tissue after transsphenoidal adenomectomy. Clin Nucl Med 39:605–608PubMedCrossRef
28.
MacMaster FP, Keshavan M, Mirza Y et al (2007) Development and sexual dimorphism of the pituitary gland. Life Sci 80:940–944PubMedCrossRef
29.
Elster AD, Chen MY, Williams DW 3rd, Key LL (1990) Pituitary gland: MR imaging of physiologic hypertrophy in adolescence. Radiology 174:681–685PubMedCrossRef
30.
Doraiswamy PM, Potts JM, Axelson DA et al (1992) MR assessment of pituitary gland morphology in healthy volunteers: age- and gender-related differences. AJNR Am J Neuroradiol 13:1295–1299PubMedPubMedCentral
31.
Tsunoda A, Okuda O, Sato K (1997) MR height of the pituitary gland as a function of age and sex: especially physiological hypertrophy in adolescence and in climacterium. AJNR Am J Neuroradiol 18:551–554PubMedPubMedCentral
32.
National Academies of Sciences E, Medicine, Division of B, et al. The National Academies Collection: Reports funded by National Institutes of Health. In: Becker T, Chin M, Bates N, eds. Measuring Sex, Gender Identity, and Sexual Orientation. Washington (DC): National Academies Press (US) Copyright 2022 by the National Academy of Sciences. All rights reserved., 2022
33.
Riaz H, Dong P, Shahzad M, Yang L (2014) Constitutive and follicle-stimulating hormone-induced action of somatostatin receptor-2 on regulation of apoptosis and steroidogenesis in bovine granulosa cells. J Steroid Biochem Mol Biol 141:150–159PubMedCrossRef
34.
Kimura N, Hayafuji C, Konagaya H, Takahashi K (1986) 17 beta-estradiol induces somatostatin (SRIF) inhibition of prolactin release and regulates SRIF receptors in rat anterior pituitary cells. Endocrinology 119:1028–1036PubMedCrossRef
35.
Djordjijevic D, Zhang J, Priam M et al (1998) Effect of 17beta-estradiol on somatostatin receptor expression and inhibitory effects on growth hormone and prolactin release in rat pituitary cell cultures. Endocrinology 139:2272–2277PubMedCrossRef
36.
Visser-Wisselaar HA, Van Uffelen CJ, Van Koetsveld PM et al (1997) 17-beta-estradiol-dependent regulation of somatostatin receptor subtype expression in the 7315b prolactin secreting rat pituitary tumor in vitro and in vivo. Endocrinology 138:1180–1189PubMedCrossRef
37.
Lin X, Janovick JA, Cardenas R, Conn PM, Peter RE (2000) Molecular cloning and expression of a type-two somatostatin receptor in goldfish brain and pituitary. Mol Cell Endocrinol 166:75–87PubMedCrossRef
38.
Yan M, Jones ME, Hernandez M, Liu D, Simpson ER, Chen C (2005) Oestrogen replacement in vivo rescues the dysfunction of pituitary somatotropes in ovariectomised aromatase knockout mice. Neuroendocrinology 81:158–166PubMedCrossRef
39.
Señarís RM, Lago F, Diéguez C (1996) Gonadal regulation of somatostatin receptor 1, 2 and 3 mRNA levels in the rat anterior pituitary. Brain Res Mol Brain Res 38:171–175PubMedCrossRef
40.
Canosa LF, Lin X, Peter RE (2003) Effects of sex steroid hormones on the expression of somatostatin receptors sst1 and sst5 in goldfish pituitary and forebrain. Neuroendocrinology 78:81–89PubMedCrossRef
41.
Dinç H, Esen F, Demirci A, Sari A, Resit GH (1998) Pituitary dimensions and volume measurements in pregnancy and post partum. MR assessment Acta Radiol 39:64–69PubMed
42.
43.
Grams AE, Gempt J, Stahl A, Förschler A (2010) Female pituitary size in relation to age and hormonal factors. Neuroendocrinology 92:128–132PubMedCrossRef
44.
Abech DD, Moratelli HB, Leite SC, Oliveira MC (2005) Effects of estrogen replacement therapy on pituitary size, prolactin and thyroid-stimulating hormone concentrations in menopausal women. Gynecol Endocrinol 21:223–226PubMedCrossRef
45.
Chen KX, Worley S, Foster H et al (2021) Oral contraceptive use is associated with smaller hypothalamic and pituitary gland volumes in healthy women: a structural MRI study. PLoS ONE 16:e0249482PubMedPubMedCentralCrossRef
46.
Fehrenbach U, Jadan A, Auer TA et al (2020) Obesity and pituitary gland volume - a correlation study using three-dimensional magnetic resonance imaging. Neuroradiol J 33:400–409PubMedPubMedCentralCrossRef
47.
Metadata
Title
[68 Ga]-DOTATATE PET/MR-based evaluation of physiologic somatostatin receptor 2 expression in the adult pituitary gland as a function of age and sex in a prospective cohort
Authors
Sean H. Kim
Se Jung Chris Chang
Georgiana Dobri
Sara Strauss
Eaton Lin
Vaz Zavaletta
Susan C. Pannullo
Joseph R. Osborne
Theodore H. Schwartz
Jonathan P. S. Knisely
Jana Ivanidze
Publication date
07-06-2023
Publisher
Springer US
Published in
Pituitary / Issue 4/2023
Print ISSN: 1386-341X
Electronic ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-023-01329-0

Other articles of this Issue 4/2023

Pituitary 4/2023 Go to the issue

OriginalPaper

Usefulness of a clinicopathological classification in predicting treatment-related outcomes and multimodal therapeutic approaches in pituitary adenoma patients: retrospective analysis on a Portuguese cohort of 129 patients from a tertiary pituitary center

OriginalPaper

Dabrafenib as a diagnostic and therapeutic strategy for the non-surgical management of papillary craniopharyngioma

OriginalPaper

Evaluating the burden of endogenous Cushing’s syndrome using a web-based questionnaire and validated patient-reported outcome measures

OriginalPaper

Characteristics of inflammatory and infectious diseases of the pituitary gland in patients undergoing transsphenoidal surgery

OriginalPaper

Postsurgical outcomes of nonfunctioning pituitary adenomas: a patient-level meta-analysis

OriginalPaper

Risk of impulse control disorders in patients with Cushing’s disease: do not blame cabergoline but do not give up caution
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits